In 2023, Boston Scientific Corporation's operational structure was reorganized, aggregating core businesses into two reportable segments, which reflects the company's strategy to enhance its IT capabilities and operational efficiencies. The firm’s IT capabilities have been evolving to encompass the coordination of assets and internal processes, thereby supporting business strategies and work processes. The company has emphasized the importance of mobilizing and deploying IT-based resources in combination with leveraging other strategic resources to transform into a competitive force. The financial performance in 2023 was significantly influenced by recent acquisitions, which were facilitated by improved IT governance and management capabilities. The increase in net sales was primarily driven by the strength and diversity of the product portfolio, supported by robust commercial execution and operational flexibility, indicating a strong alignment of IT capabilities with business needs. The company’s commitment to research and development reflects its focus on advancing medical technologies, which is crucial for maintaining competitive advantage and market agility. The operational net sales growth included contributions from acquisitions, underscoring the role of strategic resource allocation in enhancing IT effectiveness and overall firm performance. The company also faced challenges related to global supply chain disruptions, which impacted operational efficiency and resource management, highlighting the need for effective IT systems to navigate market dynamics. The implementation of the EU MDR has required substantial investment in compliance, which is indicative of the evolving regulatory context that affects IT capabilities. The 2023 restructuring plan aims to optimize functional capabilities and drive operational efficiencies, further integrating technology management into the business strategy. The firm’s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting, which is essential for effective decision-making and strategic alignment. The assessment of internal controls included considerations of the IT architecture and governance frameworks that support operational processes. The company’s strategic management practices are closely tied to its IT capabilities, facilitating the evaluation of performance metrics and enhancing organizational effectiveness. The focus on digital transformation and the integration of technology into business processes are critical for sustaining competitive positioning and responding to consumer demands. Overall, Boston Scientific's evolving IT capabilities are integral to its business strategy, enhancing its ability to respond to environmental opportunities and market restructuring while fostering innovation and operational excellence.